Healthcare provider profile · identity verified

Rofina Widjaja, MD

Internal Medicine · FONTANA, CA · NPI 1851449870

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	706	241
Amlodipine Besylate	Amlodipine Besylate	439	147
Losartan Potassium	Losartan Potassium	360	122
Lisinopril	Lisinopril	235	82
Rosuvastatin Calcium	Rosuvastatin Calcium	234	90
Levothyroxine Sodium	Levothyroxine Sodium	227	71
Metformin Hcl	Metformin Hcl	211	72
Omeprazole	Omeprazole	198	85
Glipizide	Glipizide	190	70
Atenolol	Atenolol	183	52
Meloxicam	Meloxicam	182	80
Hydrochlorothiazide	Hydrochlorothiazide	164	58
Albuterol Sulfate Hfa	Albuterol Sulfate	132	75
Simvastatin	Simvastatin	130	43
Gabapentin	Gabapentin	129	64
Prednisone	Prednisone	124	111
Bisoprolol Fumarate	Bisoprolol Fumarate	116	47
Cephalexin	Cephalexin	115	106
Metoprolol Tartrate	Metoprolol Tartrate	114	37
Spironolactone	Spironolactone	106	48
Ibuprofen	Ibuprofen	104	47
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	103	23
Jardiance	Empagliflozin	102	29
Humulin N	Insulin Nph Human Isophane	101	29
Potassium Chloride	Potassium Chloride	95	40
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	89	38
Alvesco	Ciclesonide	86	55
Furosemide	Furosemide	82	32
Hydralazine Hcl	Hydralazine Hcl	79	29
Alendronate Sodium	Alendronate Sodium	78	35
Metformin Hcl Er	Metformin Hcl	72	30
Doxycycline Monohydrate	Doxycycline Monohydrate	68	65
Triamcinolone Acetonide	Triamcinolone Acetonide	65	42
Terazosin Hcl	Terazosin Hcl	60	21
Pradaxa	Dabigatran Etexilate Mesylate	59	18
Pantoprazole Sodium	Pantoprazole Sodium	54	20
Allopurinol	Allopurinol	53	18
Tamsulosin Hcl	Tamsulosin Hcl	53	21
Fluoxetine Hcl	Fluoxetine Hcl	50	19
Acarbose	Acarbose	46	16
Azithromycin	Azithromycin	46	45
Clopidogrel	Clopidogrel Bisulfate	46	16
Humulin R	Insulin Regular, Human	46	15
Paxlovid	Nirmatrelvir/Ritonavir	45	45
Trazodone Hcl	Trazodone Hcl	41	19
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	38	15
Breyna	Budesonide/Formoterol Fumarate	37	24
Ciprofloxacin Hcl	Ciprofloxacin Hcl	37	34
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	35	35
Pravastatin Sodium	Pravastatin Sodium	35	11
Lactulose	Lactulose	34	23
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	33	33
Sertraline Hcl	Sertraline Hcl	33	13
Fluconazole	Fluconazole	32	31
Colchicine	Colchicine	31	12
Finasteride	Finasteride	31	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	31	12
Azelastine Hcl	Azelastine Hcl	30	14
Nystatin	Nystatin	30	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	29	29
Ezetimibe	Ezetimibe	29	12
Montelukast Sodium	Montelukast Sodium	29	suppressed
Spiriva Respimat	Tiotropium Bromide	29	suppressed
Tramadol Hcl	Tramadol Hcl	28	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	28	11
Ondansetron Hcl	Ondansetron Hcl	27	14
Amoxicillin	Amoxicillin	26	24
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	25	suppressed
Carvedilol	Carvedilol	24	suppressed
Clobetasol Propionate	Clobetasol Propionate	24	17
Famotidine	Famotidine	24	12
Fluticasone Propionate	Fluticasone Propionate	24	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	24	suppressed
Topiramate	Topiramate	23	12
Hydrocortisone	Hydrocortisone	22	19
Oxybutynin Chloride Er	Oxybutynin Chloride	22	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	21	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	20	19
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	19	18
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	19	18
Veo Insulin Syringe	Syrge-Ndl,ins 0.3 Ml Half Mark	19	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	18	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	18	suppressed
Metoprolol Succinate	Metoprolol Succinate	18	suppressed
Naproxen	Naproxen	18	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	17	suppressed
Metronidazole	Metronidazole	17	15
Pregabalin	Pregabalin	17	suppressed
Verapamil Er	Verapamil Hcl	17	suppressed
Clonidine Hcl	Clonidine Hcl	16	suppressed
Fenofibrate	Fenofibrate	16	suppressed
Naloxone Hcl	Naloxone Hcl	16	16
Warfarin Sodium	Warfarin Sodium	16	suppressed
Diltiazem Hcl	Diltiazem Hcl	15	suppressed
Lorazepam	Lorazepam	15	suppressed
Neomycin-Polymyxin-Dexameth	Neomycin/Polymyxin B/Dexametha	15	15
Ozempic	Semaglutide	15	suppressed
Acyclovir	Acyclovir	14	suppressed
Eliquis	Apixaban	14	suppressed
Primidone	Primidone	14	suppressed
Buspirone Hcl	Buspirone Hcl	13	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	13	suppressed
Tradjenta	Linagliptin	13	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	13	suppressed
Xarelto	Rivaroxaban	13	suppressed
Cartia Xt	Diltiazem Hcl	12	suppressed
Estradiol	Estradiol	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Propranolol Hcl	Propranolol Hcl	12	suppressed
Colestipol Hcl	Colestipol Hcl	11	suppressed
Duloxetine Hcl	Duloxetine Hcl	11	suppressed
Glipizide Er	Glipizide	11	suppressed
Humalog	Insulin Lispro	11	suppressed
Lovastatin	Lovastatin	11	suppressed
Mupirocin	Mupirocin	11	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error